On April 3, 2017 Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, reported that the Company has been selected for two poster presentations on its Antibody-Coupled T cell Receptor (ACTR) platform at the AACR (Free AACR Whitepaper) 2017 Annual Meeting, which is being held in Washington DC, April 1-5, 2017 (Press release, Unum Therapeutics, APR 3, 2017, View Source [SID1234518436]). The first poster presentation will highlight data from non-clinical studies on targeting BCMA-positive multiplemyeloma cells with ACTR in combination with a humanized non-fucosylated anti-BCMA antibody, SEA-BCMA, developed using Seattle Genetics’ novel sugar-engineered antibody (SEA) technology. This is the first named program under Unum’s global collaboration with Seattle Genetics. The second poster will provide data from exploratory work on targeting Glypican-3 (GPC3) with ACTR in combination with an anti-GPC3 antibody, one of the targets that the companies are also investigating under their collaboration. Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The accepted abstracts are listed below and are available online on the AACR (Free AACR Whitepaper) 2017 conference website: www.aacr.org.
Presentation Details:
Abstract Number: 4605
Title: Efficient targeting of BCMA-positive multiple myeloma cells by Antibody-Coupled T cell Receptor (ACTR) engineered autologous T cells in combination with an anti-BCMA antibody
Authors: Tooba Cheema, Taylor Hickman, Katie O’Callaghan, *Lori Westendorf, *Luke Manlove, *Shyra Gardai, Allison Nelson, Ryan Boomer, Kathleen McGinness, Birgit Schultes, Seth Ettenberg, *Django Sussman and Heather Huet.
Authors’ Affiliation: Unum Therapeutics, *Seattle Genetics
Presenter: Tooba Cheema, Senior Scientist, Unum Therapeutics
Session: Immunoconjugates and Antibodies
Session Date and Time: April 4, 2017, 1:00 – 5:00 PM
Location: Convention Center, Halls A-C, Poster Section 26
Poster Board Number: 20
Abstract Number: 3762
Title: Superior T cell activity of a membrane-proximal binding antibody when targeting Glypican-3 with an Antibody-Coupled T cell Receptor (ACTR) armed T cell
Authors: Greg Motz, John Shin, Kathy Whiteman, Birgit Schultes, Tapasya Pai, Lori Westendorf*, Seth Ettenberg, Travis Biechele*, Django Sussman* and Heather Huet
Authors’ Affiliation: Unum Therapeutics, *Seattle Genetics
Presenter: Greg Motz, Senior Scientist, Unum Therapeutics
Session: Innate Effectors in Immunity to Cancer
Session Date and Time: April 4, 2017, 8:00 – 12:00 PM
Location: Convention Center, Halls A-C, Poster Section 30
Poster Board Number: 18
The posters will be posted on Unum’s website following the presentations.
About Antibody-Coupled T cell Receptor (ACTR) Technology
Unum’s proprietary ACTR is a chimeric protein that combines components from receptors normally found on two different human immune cell types – natural killer (NK) cells and T cells – to create a novel approach to cancer cell killing. T cells bearing the ACTR receptor protein can be directed to attack a tumor by combining with a monoclonal antibody that binds antigens on the cancer cell surface.
In contrast to other T cell therapy approaches for cancer that are limited to a single cancer cell surface target and, therefore, treat a narrow set of tumors, Unum’s approach is not restricted by a specific tumor cell antigen and, thus, may have applications for treating many different types of cancers when combined with the right antibody.
Unum is developing ACTR in combination with a range of tumor-targeting antibodies for use in both hematologic and solid tumor indications. ACTR087, Unum’s most advanced product candidate, combines Unum’s proprietary ACTR with rituximab, an anti-CD20 antibody. The ACTR087 study is the first clinical trial using a viral vector to permanently insert the ACTR gene into the genome of patients’ T cells.